Psychological Distress, Symptom Burden and Quality of Life in Patients with Mycosis Fungoides and Sézary Syndrome
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0463Keywords:
mycosis fungoides, Sézary Syndrome, Quality of Life, Depression, AnxietyAbstract
Mycosis fungoides (MF) and Sézary syndrome (SS) are rare cutaneous lymphomas with limited data on psychological burden. This observational, cross sectional questionnaire study assessed symptom burden, psychological distress and quality of life (QoL) in patients with MF and SS in Western Sweden and compared outcomes with psoriasis. Sixty patients were included, 80% with early-stage disease. Most reported minimal depression, anxiety and QoL impairment. Moderate-to-severe depression occurred in 36% of advanced disease cases and 16% of early disease cases and moderate-to-severe QoL impairment in 33% and 17%, respectively. Pruritus correlated strongly with impaired QoL (ρ=0.67, p<0.001). Fatigue correlated with depression (Montgomery–Åsberg Depression Rating Scale Self-report (MADRS-S): ρ=0.60, Hospital Anxiety and Depression Scale-Depression subscale: ρ=0.63), anxiety (ρ=0.49) and QoL impairment (ρ=0.53), all p<0.001. Compared with psoriasis, patients reported lower pain and QoL impairment. Overall, psychological burden was limited but increased with advanced disease and fatigue severity.
Downloads
References
Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv30–iv40. DOI: https://doi.org/10.1093/annonc/mdy133
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–3785. DOI: https://doi.org/10.1182/blood-2004-09-3502
Wieselthier JS, Koh HK. Sézary syndrome: Diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 1990; 22: 381–401. DOI: https://doi.org/10.1016/0190-9622(90)70054-L
Miyashiro D, Sanches JA. Mycosis fungoides and Sézary syndrome: Clinical presentation, diagnosis, staging, and therapeutic management. Front Oncol 2023; 13: 1141108. DOI: https://doi.org/10.3389/fonc.2023.1141108
Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: Results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006; 107: 2504–2511. DOI: https://doi.org/10.1002/cncr.22252
Demierre MF, Tien A, Miller D. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol 2005; 141: 325–330. DOI: https://doi.org/10.1001/archderm.141.3.325
Herbosa CM, Semenov YR, Rosenberg AR, Mehta-Shah N, Musiek AC. Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and Sézary syndrome: Comparison of generic and dermatology-specific instruments. J Eur Acad Dermatol Venereol 2020; 34: 995–1003. DOI: https://doi.org/10.1111/jdv.16021
Molloy K, Jonak C, Woei-A-Jin FJSH, Guenova E, Busschots AM, Bervoets A, et al. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol 2020; 182: 770–779. DOI: https://doi.org/10.1111/bjd.18089
Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. JAAD Int 2022; 9: 57–64. DOI: https://doi.org/10.1016/j.jdin.2022.07.007
Shinohara MM, Mahurin HM, Tarabadkar E, Hippe DS, Lachance K, Kim EJ, et al. Health-related quality of life in cutaneous T-cell lymphoma: A cross-sectional survey study. Skin Health Dis 2021; 1: e45. DOI: https://doi.org/10.1002/ski2.45
Wright A, Wijeratne A, Hung T, Gao W, Whittaker S, Morris S, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. J Pain Symptom Manage 2013; 45: 114–119. DOI: https://doi.org/10.1016/j.jpainsymman.2012.01.012
Graier T, Fink-Puches R, Porkert S, Lang R, Pöchlauer S, Quality of life, anxiety, and depression in patients with early-stage mycosis fungoides and the effect of oral psoralen plus UV-A (PUVA) photochemotherapy on it. Front Med (Lausanne) 2020; 7: 330. DOI: https://doi.org/10.3389/fmed.2020.00330
Holahan HM, Farah RS, Fitz S, Mott SL, Ferguson NN, McKillip J, et al. Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol 2018; 57: 1314–1319. DOI: https://doi.org/10.1111/ijd.14132
Nenonen J, Winther AH, Jonsson P, Ivert LU, Brauner H. Identification of subgroups of early-stage mycosis fungoides patients with increased itch and impaired quality of life. Front Oncol 2025; 15: 1524353. DOI: https://doi.org/10.3389/fonc.2025.1524353
Quaglino P, Prince HM, Cowan R, Vermeer M, Papadavid E, Bagot M, et al. Treatment of early-stage mycosis fungoides: Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol 2021; 184: 722–730. DOI: https://doi.org/10.1111/bjd.19252
Sánchez-Merino A, Vílchez-Márquez F, Núñez-García A, Botella-García C, Arias-Santiago S. [Translated article] Analyzing the quality of life of individuals with cutaneous lymphomas. Actas Dermosifiliogr 2025; 116: T1001–T1006. DOI: https://doi.org/10.1016/j.ad.2025.07.014
Semenov YR, Rosenberg AR, Herbosa C, Mehta-Shah N, Musiek AC. Health-related quality of life and economic implications of cutaneous T-cell lymphoma. Br J Dermatol 2020; 182: 190–196. DOI: https://doi.org/10.1111/bjd.17941
Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: A systematic review of the literature. J Eur Acad Dermatol Venereol 2021; 35: 2377–2387. DOI: https://doi.org/10.1111/jdv.17570
Balan K, Lallas A, Akdogan N. Patterns and pitfalls: Dermoscopic differentiation of early-stage mycosis fungoides, atopic dermatitis, and psoriasis. J Am Acad Dermatol 2026; 94: 1193–1198. DOI: https://doi.org/10.1016/j.jaad.2025.12.049
Wojewoda K, Gillstedt M, Englund H, Ali S, Lewerin C, Osmancevic A. Diagnostic outcomes and treatment modalities in patients with mycosis fungoides in west Sweden-A retrospective register-based study. Cancers (Basel) 2022; 14: 14. DOI: https://doi.org/10.3390/cancers14194661
Wojewoda K, Gillstedt M, Lewerin C, Osmancevic A. Sézary syndrome in west Sweden: Exploring epidemiology, clinical features, and treatment patterns in a registry-based retrospective analysis. Cancers (Basel) 2024; 16: 1948. DOI: https://doi.org/10.3390/cancers16111948
Evers AWM, Duller P, van de Kerkhof PCM, van der Valk PGM, de Jong EMGJ, Gerritsen MJP, et al. The Impact of Chronic Skin Disease on Daily Life (ISDL): Aa generic and dermatology-specific health instrument. Br J Dermatol 2008; 158: 101–108.
Svanborg P, Asberg M. A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). J Affect Disord 2001; 64: 203–216. DOI: https://doi.org/10.1016/S0165-0327(00)00242-1
Herrmann C. International experiences with the Hospital Anxiety and Depression Scale--A review of validation data and clinical results. J Psychosom Res 1997; 42: 17–41. DOI: https://doi.org/10.1016/S0022-3999(96)00216-4
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--A simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216. DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Cunningham JL, Wernroth L, von Knorring L, Berglund L, Ekselius L. Agreement between physicians’ and patients’ ratings on the Montgomery-Åsberg Depression Rating Scale. J Affect Disord 2011; 135: 148–153. DOI: https://doi.org/10.1016/j.jad.2011.07.005
Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes 2003; 1: 29. DOI: https://doi.org/10.1186/1477-7525-1-29
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659–664. DOI: https://doi.org/10.1111/j.0022-202X.2005.23621.x
Damiani G, Tacastacas JD, Wuerz T, Miller L, Fastenau P, Bailey C, et al. Cognition/psychological burden and resilience in cutaneous T-cell lymphoma and psoriasis patients: real-life data and implications for the treatment. Biomed Res Int 2022; 2022: 8802469. DOI: https://doi.org/10.1155/2022/8802469
Engin B, Keçici AS, Uzun AÖ, Yalçın M. Psychiatric comorbidity, depression, and anxiety levels and quality of life of the patients with mycosis fungoides. Dermatol Ther 2020; 33: e13922. DOI: https://doi.org/10.1111/dth.13922
Sampogna F, Frontani M, Baliva G, Lombardo GA, Alvetreti G, Di Pietro C, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol 2009; 160: 815–822. DOI: https://doi.org/10.1111/j.1365-2133.2008.08992.x
Segal O, Trumper N, Pavlotsky F, Goldzweig G, Barzilai A. Illness perception, coping, and quality of life in early-stage Mycosis fungoides. An Bras Dermatol 2021; 96: 27–33. DOI: https://doi.org/10.1016/j.abd.2020.05.008
Melrose S. Seasonal affective disorder: An overview of assessment and treatment approaches. Depress Res Treat 2015; 2015: 178564. DOI: https://doi.org/10.1155/2015/178564
Bhat TS, Herbosa CM, Rosenberg AR, Sogade O, Jeffe DB, Mehta-Shah N, et al. Current measures are not sufficient: An interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma. Br J Dermatol 2021; 184: 310–318. DOI: https://doi.org/10.1111/bjd.19298
Bower JE. Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 2014; 11: 597–609. DOI: https://doi.org/10.1038/nrclinonc.2014.127
Tamer F, Aypek Y, Adisen E. How does mycosis fungoides affect quality of life? Comparative evaluation of the Dermatology Life Quality Index in patients with mycosis fungoides and psoriasis. Proc (Bayl Univ Med Cent) 2025; 38: 427–433. DOI: https://doi.org/10.1080/08998280.2025.2500853
Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol 2017; 76: 393–403. DOI: https://doi.org/10.1016/j.jaad.2016.07.065
Johnson CM, Talluru SM, Bubic B, Colbert M, Kumar P, Tsai HL, et al. Association of cardiovascular disease in patients with Mycosis fungoides and Sézary syndrome compared to a matched control cohort. JID Innov 2023; 3: 100219. DOI: https://doi.org/10.1016/j.xjidi.2023.100219
Additional Files
Published
How to Cite
License
Copyright (c) 2026 Rudy Bittar, Karolina Wojewoda, Martin Gillstedt, Catharina Lewerin, Mikael Alsterholm, Amra Osmancevic
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
